The May issue of the Journal of Nuclear Medicine features an editorial supplement on the usefulness of PET imaging for the treatment of several cancers.
Personalizing Cancer Therapy with FDG PET: From RECIST to PERCIST is designed as a reference tool with the most up-to-date information about the use of FDG and PET for monitoring therapy and treatment of different cancers.
"The reason for [the supplement] was that we know there are multiple studies that looked at PET and FDG to examine the metabolic rate of response by tumors to treatment," said JNM Editor-in-Chief Dr. Heinrich Schelbert, professor of molecular and medical pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles. "The idea was to put all this material together for a variety of cancers and to see what the outcomes were."
Internationally recognized PET imaging specialists and oncologists contributed to the supplement, Schelbert said, which has been in the works since last fall.
"It was our feeling that we needed to put this together so that FDG-PET could be used as a way to monitor treatment, to assess whether a patient did respond to a given treatment, and whether it can be used in the future to personalize treatment or adjust treatment in a given patient," he added.
Related Reading
SNM hosts cardiovascular symposium, May 4, 2009
Prototype PET phantom successfully tested, April 15, 2009
SNM, CMOD plan May PET meeting, March 27, 2009
FDA clears SNM IND application, February 3, 2009
SNM criticizes NAS isotope report, January 16, 2009
Copyright © 2009 AuntMinnie.com
